Direct Current Cardioversion of Atrial Fibrillation in Patients With Left Atrial Appendage Occlusion Devices

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:74

Article

Sharma, Sharan Prakash^1,2  Turagam, Mohit K.³  Gopinathannair, Rakesh^1,2  Reddy, Vivek³  Kar, Saibal⁴  Mohanty, Sangamitra⁵  Cheng, Jie⁶  Holmes, David R., Jr.⁷  Sondergaard, Lars⁸  Natale, Andrea⁵  Lakkireddy, Dhanunjaya^1,2 

[1] Kansas City Heart Rhythm Inst, Overland Pk, KS USA

[2] Res Fdn, Overland Pk, KS USA

[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[5] St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, Austin, TX USA

[6] St Lukes Hosp, Texas Heart Inst, Houston, TX USA

[7] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA

[8] Univ Copenhagen, Rigshosp, Heart Ctr, Copenhagen, Denmark

关键词: direct current cardioversion;    left atrial appendage occlusion;    oral anticoagulation;    Watchman;   

DOI  :  10.1016/j.jacc.2019.08.1045

来源: Elsevier

【 摘 要 】

BACKGROUND Direct current cardioversion (DCCV) is a common rhythm control strategy in patients with symptomatic atrial fibrillation or flutter. There is no long-term data regarding the safety of DCCV in patients with endocardial left atrial appendage occlusion (LAAO) devices. OBJECTIVES The purpose of this study was to assess the feasibility and safety of DCCV in patients with an LAAO device. METHODS This multicenter retrospective study included 148 patients with an LAAO device who underwent DCCV for symptomatic atrial fibrillation or atrial flutter. RESULTS The average age of the included patients was 72 +/- 7 years and 59% were men. All patients (100%) had a transesophageal echocardiogram prior to DCCV. Device-related thrombus was seen in 2.7%. They were all successfully treated with oral anticoagulation (OAC) and were able to undergo DCCV after 6 to 8 weeks. DCCV restored sinus rhythm in all patients. None of the patients had DCCV-related thromboembolic complications. A total of 22% of patients were newly started on OAC after DCCV. There was no difference in DCCV-related complications between patients treated with or without OAC post-DCCV. Patients receiving OAC post-DCCV were found to undergo cardioversion at an earlier time after implantation (3.6 months [interquartile range (IQR): 0.7 to 8.6 months] vs. 8.6 months [IQR: 2.5 to 13.3 months]; p = 0.003). Three transient ischemic attacks, unrelated to DCCV, were found during follow-up. During a median follow-up of 12.8 months (IQR: 11.8 to 14.2 months), no device or left atrial thrombosis, device dislodgement, or a new device leak were observed. One patient died during follow-up due to noncardiac cause. CONCLUSIONS DCCV is feasible in high-risk AF patients with an LAAO device without the need for oral anticoagulation if pre-procedural transesophageal echocardiography shows good device position, absence of device-related thrombus, and peridevice leak of <= 5 mm. The preliminary results are encouraging, but further large studies are warranted to establish safety. (C) 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.

【 授权许可】

Free